Topic: glioblastoma multiforme (GBM)
TwoXAR's drug discovery partnership with South Korea’s 1ST Biotherapeutics is the company's third.
A phase 3 study from imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in glioma diagnoses.
A UCSF spinoff is working with GlaxoSmithKline to develop a drug to target a common mutation in glioblastoma.
Novocure named Pritesh Shah chief commercial officer, to lead the tumor-treating device manufacturer’s international business units.
The team behind a much-hyped cancer-killing virus reports an "encouraging" long-term survival rate in glioblastoma patients.
A modified form of poliovirus seems to shrink breast tumors by latching onto a protein that's heavily expressed on the surface of some cancer cells.
Northwest Bio unveiled interim phase 3 data showing its dendritic cell vaccine improved survival rates in patients with newly diagnosed glioblastoma.
CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.
Israeli biotech VBL Therapeutics has joined a long line of companies that have failed to move the needle against a form of aggressive brain tumor.
Targeting a "highly prevalent" antigen could address the heterogeneity of glioblastomas.